T · 4588.T
Oncolys BioPharma Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Tokyo 105-0001
- Website
- oncolys.com
Price · as of 2025-12-31
$2,797.00
Market cap 70.91B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,192.93 | -57.35% |
| Intrinsic Value(DCF) | $1,219.53 | -56.4% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $38.26 | -98.63% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $1,999.00 | $986.21 | $618.39 | $0.00 | $8,238.10 |
| 2014 | $683.00 | $832.91 | $2,842,318.82 | $16.39 | $0.00 |
| 2015 | $555.00 | $308.05 | $242.97 | $0.00 | $0.00 |
| 2016 | $1,030.00 | $427.48 | $164.19 | $0.00 | $0.00 |
| 2017 | $959.00 | $394.96 | $153.95 | $0.00 | $0.00 |
| 2018 | $3,000.00 | $1,203.72 | $100.32 | $0.00 | $1,790.03 |
| 2019 | $1,298.00 | $767.66 | $42,065.64 | $0.00 | $0.00 |
| 2020 | $1,080.00 | $432.00 | $3.86 | $0.00 | $9,399.20 |
| 2021 | $561.00 | $233.30 | $1,557.08 | $0.00 | $0.00 |
| 2022 | $640.00 | $256.00 | $1,268.39 | $0.00 | $0.00 |
| 2023 | $636.00 | $254.40 | $0.00 | $0.00 | $8,866.16 |
| 2024 | $694.00 | $284.29 | $32.68 | $0.00 | $3,078.19 |
| 2025 | $2,956.00 | $1,192.93 | $61.88 | $0.00 | $38.26 |
AI valuation
Our deep-learning model estimates Oncolys BioPharma Inc.'s (4588.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,192.93
- Current price
- $2,797.00
- AI upside
- -57.35%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1,219.53
-56.4% upside
Graham-Dodd
—
— upside
Graham Formula
$38.26
-98.63% upside
About Oncolys BioPharma Inc.
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
- CEO
- Yasuo Urata
- Employees
- 40
- Beta
- 0.71
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1,219.53 ÷ $2,797.00) − 1 = -56.4% (DCF, example).